RATIONALLY-SELECTED MICROBIOTA™
PLATFORM

SCIENCE & PLATFORMS

THE MICROBIOME

HUMAN-FIRST
DISCOVERY PLATFORM

FULL-SPECTRUM
MICROBIOTA
PLATFORM

**RATIONALLY-SELECTED
MICROBIOTA
PLATFORM**

IP PORTFOLIO

RATIONALLY-SELECTED MICROBIOTA (RSM™)
THERAPIES ARE DEFINED GROUPS OF HUMAN-DERIVED
MICROBES, CAREFULLY SELECTED FOR THEIR ABILITY TO
INTERACT WITH OTHER MICROBES AND THE HOST TO
DRIVE CLINICAL RESULTS.

Finch's *RSM* platform employs machine-learning algorithms to mine our unique clinical datasets, reverse engineering successful clinical experience with *Full Spectrum Microbiota* to identify the key microbes driving patient outcomes. Using machine learning against these data sets enables Finch to determine the most effective therapy (*FSM* or *RSM*). *RSM* therapies target specific, clinically efficacious strains to create a consortium of human-adapted, therapeutic microbes. By enabling the strategic selection of compositions already validated in patients, Finch is introducing a new and rapidly scalable class of microbial therapies.

FIN-524, a microbial cocktail for ulcerative colitis, is our first product candidate based on this philosophy.